Publications by authors named "Jill Clancy"

Claim this Profile
E
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer.
Joseph Chen, Alessandra Bearz, Dong-Wan Kim, Hirva Mamdani, Jessica Bauman, Jill S Clancy

Clin Pharmacokinet· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to "Lorlatinib Exposed: A Far from Optimal Dose".
Joseph Chen, Ana Ruiz-Garcia, Leonard P James, Gerson Peltz, Holger Thurm, Jill Clancy

Clin Pharmacol Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer.
Joseph Chen, Ana Ruiz-Garcia, Leonard P James, Gerson Peltz, Holger Thurm, Jill Clancy

Clin Pharmacol Ther· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
Solange Peters, Alice T Shaw, Benjamin Besse, Enriqueta Felip, Benjamin J Solomon, Jill S Clancy

Lung Cancer· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Alice T Shaw, Benjamin J Solomon, Rita Chiari, Gregory J Riely, Benjamin Besse, Jill S Clancy

Lancet Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Alice T Shaw, Benjamin J Solomon, Benjamin Besse, Todd M Bauer, Chia-Chi Lin, Jill S Clancy

J Clin Oncol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, Enriqueta Felip, Ross A Soo, Jill S Clancy

Lancet Oncol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma.
Wojciech Jurczak, Sundra Ramanathan, Pratyush Giri, Alessandra Romano, Heidi Mocikova, Jill Clancy

Leuk Lymphoma· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Alice T Shaw, Enriqueta Felip, Todd M Bauer, Benjamin Besse, Alejandro Navarro, Jill S Clancy

Lancet Oncol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
Brian I Rini, Joaquim Bellmunt, Jill Clancy, Kongming Wang, Andreas G Niethammer

J Clin Oncol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma.
Birgit Geoerger, Mark W Kieran, Stephan Grupp, Danuta Perek, Jill Clancy

Eur J Cancer· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.
Sheri L Spunt, Stephan A Grupp, Terry A Vik, Victor M Santana, David J Greenblatt, Jill Clancy

J Clin Oncol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
Georg Hess, Raoul Herbrecht, Jorge Romaguera, Gregor Verhoef, Michael Crump, Jill Clancy

J Clin Oncol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis